Skip to content

Research at St Andrews

Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

Research output: Contribution to journalArticle

Author(s)

Mohamed I. M. Ahmed, Nyanda E. Ntinginya, Gibson Kibiki, Bariki A Mtafya, Hadija Semvua, Stellah Mpagama, Charles Mtabho, Elmar Saathoff, Kathrin Held, Rebecca Loose, Inge Kroidl, Mkunde Chachage, Ulrich von Both, Antelmo Haule, Anna-Maria Mekota, Martin J. Boeree, Stephen H. Gillespie, Michael Hoelscher, Norbert Heinrich, Christof Geldmacher & 1 more Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA)

School/Research organisations

Abstract

Background: The analysis of phenotypic characteristics on Mycobacterium tuberculosis (MTB)-specific T cells is a promising approach for the diagnosis of active tuberculosis (aTB) and for monitoring treatment success. We therefore studied phenotypic changes on MTB-specific CD4 T cells upon anti-tuberculosis treatment initiation in relation to the treatment response as determined by sputum culture.

Methods: Peripheral blood mononuclear cells from subjects with latent MTB infection (n=16) and aTB (n=39) at baseline, week 9, 12 and 26 (end of treatment) were analyzed after intracellular interferon gamma staining and overnight stimulation with tuberculin. Liquid sputum cultures were performed weekly until week 12 and during 4 visits until week 26.

Results: T cell activation marker expression on MTB-specific CD4 T cells differed significantly between subjects with aTB and latent MTB infection with no overlap for the frequencies of CD38pos and Ki67pos cells (both p < 0.0001). At 9 weeks after anti-TB treatment initiation the frequencies of activation marker (CD38, HLA-DR, Ki67) positive MTB-specific, but not total CD4 T cells, were significantly reduced (p < 0.0001). Treatment induced phenotypic changes from baseline until week 9 and until week 12 differed substantially between individual aTB patients and correlated with an individual's time to stable sputum culture conversion for expression of CD38 and HLA-DR (both p < 0.05). In contrast, the frequencies of maturation marker CD27 positive MTB-specific CD4 T cells remained largely unchanged until week 26 and significantly differed between subjects with treated TB disease and latent MTB infection (p = 0.0003).

Discussion: Phenotypic changes of MTB-specific T cells are potential surrogate markers for tuberculosis treatment efficacy and can help to discriminate between aTB (profile: CD38pos, CD27low), treated TB (CD38neg, CD27low), and latent MTB infection (CD38neg, CD27high).
Close

Details

Original languageEnglish
Article number2247
Number of pages13
JournalFrontiers in Immunology
Volume9
DOIs
Publication statusPublished - 28 Sep 2018

    Research areas

  • TAM-TB assay, Tuberculosis, Treatment monitoring, Mycobacterium tuberculosis-specific T cells, Serial sputum culture, Biomarker

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Modelling the effects of environmental heterogeneity within the lung on the tuberculosis life-cycle

    Pitcher, M. J., Bowness, R., Dobson, S. A., Eftimie, R. & Gillespie, S. H., 6 Aug 2020, In : Journal of Theoretical Biology. 506, 18 p., 110381.

    Research output: Contribution to journalArticle

  2. Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria

    Heyckendorf, J., Gillespie, S. H. & Ruhwald, M., 10 Nov 2020, In : EBioMedicine. 62, 2 p., 103117.

    Research output: Contribution to journalComment/debate

  3. Perspective for precision medicine for tuberculosis

    Lange, C., Aarnoutse, R., Chesov, D., van Crevel, R., Gillespie, S. H., Grobbel, H-P., Kalsdorf, B., Kontsevaya, I., van Laarhoven, A., Nishiguchi, T., Mandalakas, A., Merker, M., Niemann, S., Köhler, N., Heyckendorf, J., Reimann, M., Ruhwald, M., Sanchez-Carballo, P., Schwudke, D., Waldow, F. & 1 others, DiNardo, A. R., 8 Oct 2020, In : Frontiers in Immunology. 11, 9 p., 566608.

    Research output: Contribution to journalReview article

Related by journal

  1. Frontiers in Immunology (Journal)

    Val Smith (Member of editorial board)

    20172018

    Activity: Publication peer-review and editorial work typesPeer review of manuscripts

Related by journal

  1. Atherosclerosis linked to aberrant amino acid metabolism and immunosuppressive amino acid catabolizing enzymes

    Zaric, B. L., Radovanovic, J. N., Gluvic, Z., Stewart, A. J., Essak, M., Motwalli, O., Gojobori, T. & Isenovic, E. R., 28 Sep 2020, In : Frontiers in Immunology. 11, 27 p., 551758.

    Research output: Contribution to journalReview article

  2. Perspective for precision medicine for tuberculosis

    Lange, C., Aarnoutse, R., Chesov, D., van Crevel, R., Gillespie, S. H., Grobbel, H-P., Kalsdorf, B., Kontsevaya, I., van Laarhoven, A., Nishiguchi, T., Mandalakas, A., Merker, M., Niemann, S., Köhler, N., Heyckendorf, J., Reimann, M., Ruhwald, M., Sanchez-Carballo, P., Schwudke, D., Waldow, F. & 1 others, DiNardo, A. R., 8 Oct 2020, In : Frontiers in Immunology. 11, 9 p., 566608.

    Research output: Contribution to journalReview article

  3. Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer

    Moon, W. Y. & Powis, S. J., 19 Jul 2019, In : Frontiers in Immunology. 10, 5 p., 1703.

    Research output: Contribution to journalReview article

ID: 256162851

Top